Navigation Links
Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
Date:6/14/2008

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulator
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
2. QLT announces positive Health Canada decision on Aczone(R)
3. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
4. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
5. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
6. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Liver Diseases: A Huge European Health Burden, But Some Trends are Positive
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies ... technologies, today announced that their third Phase ... reduction of recurrence of hypertrophic scars following ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing novel ... of seed financing from friends and family investors. Proceeds ... a novel sustained-release product for ophthalmology. , "We are ... commitment to this important work," said Dr. Ken Mandell, ... many areas in which innovations in drug delivery have ...
(Date:7/29/2014)... have hurdled a number of significant technological challenges ... observing technology originally created for the James Webb ... Investigator Harvey Moseley, a scientist at NASA,s Goddard ... that electrostatically actuated microshutter arrays that is, ... are as functional as the current technology,s magnetically ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... Gov. Jim Doyle vetoed a bill that would have banned ... legislative director of Wisconsins Right to Life movement made a ... , ,We're not talking about stem cells anymore; we're talking ... cells but for organs and body parts, Right to Lifes ...
... proliferates the American landscape, Google is achieving ... not go by that Google's brand and services don't touch ... media, and business owner. , ,The seven-year-old company, which ... public just 15 months ago at $85 and closed at ...
... - Last week Gov. Jim Doyle announced a new ... to further the adoption of electronic medical records in Wisconsin. ... power of information technology at the most important point in ... a statement, citing statistics showing 30 percent of healthcare costs ...
Cached Biology Technology:Separating science fiction from reality in the human cloning debate 2Separating science fiction from reality in the human cloning debate 3Are you a citizen of the "Google Nation?" 2Are you a citizen of the "Google Nation?" 3Wisconsin pushes for adoption of electronic health records 2
(Date:7/29/2014)... sperm, bacteria and algae, propel themselves using whip-like ... of a millimetre long, function like tiny oars, ... called cilia are found on the surfaces of ... moving liquids over the cell. , Flagella ... and expel pathogens from our airways, they establish ...
(Date:7/28/2014)... communities showing signs of damage from the Deepwater Horizon oil ... the Gulf of Mexico. The discovery was made by a ... State University. A paper describing this work and additional impacts ... will be published during the last week of July 2014 ... of the National Academy of Sciences . , "The footprint ...
(Date:7/28/2014)... the United States have a circulatory problem of the ... and may even require surgery in serious cases. This ... in turn, limb amputation. , At The University of ... scientists tested a non-surgical preventative treatment in a mouse ... increased blood circulation. Their proof-of-concept study appears in ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... On the tenth anniversary of the completion of the first draft ... years to complete the Wellcome Trust today launches a project ... years. This will be one of the largest genome sequencing programmes ... one in 6,000 people in the UK. The UK10K project ...
... This release is available in German . ... Houbara bustards - a North African bird species with ... visual stimulation from attractive males of the same species ... that observed highly displaying male birds in the experiment ...
... Technology (NIST) scientists have moved a step closer to developing ... scan for thousands of disease markers and other chemical indicators ... decode the electrical signals generated by a nanoporea "gate" less ... Nanopores are not new themselves; for more than a decade, ...
Cached Biology News:Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 2Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 3Pleasing to the eye 2Pleasing to the eye 3NIST team advances in translating language of nanopores 2
UBC13 Antibody...
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Phenytoin-BSA Isolated IgY DFc Drug...
Tropomyosin 4 [Tm4]...
Biology Products: